Llwytho...
Steroid sidestep: Evading androgen ablation by abiraterone
Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well-defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in subset of patients progressing while receiving abiraterone, suggesting this may be a therapeutically exploitable mechanism of abir...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Cancer Res |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2014
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4359949/ https://ncbi.nlm.nih.gov/pubmed/25432158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2899 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|